Abstract

Patients with intellectual disability, autism spectrum disorder, cerebral palsy, or severe dental fear often have difficulty undergoing routine outpatient dental treatment, leading to repeated delays or treatment failure. In such cases, sedation may serve as an important option bridging general anesthesia and routine outpatient care. Remimazolam is a recently introduced sedative and general anesthetic agent approved in major regions. This article reviews the clinical signifi cance of remimazolam in dental treatment for patients with disabilities and summarizes the rationale for considering it as an agent for dental sedation. (J Korean Dent Assoc 2026; 64(4): 143-150)